Status Awaiting development
Process HST
ID number 3995

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
07 September 2021 Sebelipase alfa has been identified as appropriate for potential guidance development as a Highly Specialised Technology (HST) for treating Wolman disease.

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance